Axa S.A. Takes Position in MaxCyte, Inc. (NASDAQ:MXCT)

AXA S.A. purchased a new position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 986,897 shares of the company's stock, valued at approximately $4,105,000. AXA S.A. owned approximately 0.93% of MaxCyte as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Barclays PLC increased its holdings in MaxCyte by 329.3% during the 3rd quarter. Barclays PLC now owns 165,765 shares of the company's stock worth $645,000 after purchasing an additional 127,156 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of MaxCyte by 47.9% during the fourth quarter. Renaissance Technologies LLC now owns 281,200 shares of the company's stock worth $1,170,000 after buying an additional 91,100 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of MaxCyte by 51.4% during the fourth quarter. Hsbc Holdings PLC now owns 48,791 shares of the company's stock worth $199,000 after buying an additional 16,554 shares in the last quarter. Rice Hall James & Associates LLC bought a new stake in shares of MaxCyte in the fourth quarter worth $1,098,000. Finally, Gagnon Securities LLC raised its holdings in MaxCyte by 234.1% in the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company's stock valued at $821,000 after acquiring an additional 138,257 shares in the last quarter. Institutional investors and hedge funds own 68.81% of the company's stock.

MaxCyte Stock Performance

Shares of NASDAQ MXCT traded down $0.04 during trading on Tuesday, reaching $2.23. The stock had a trading volume of 199,274 shares, compared to its average volume of 541,233. The stock has a market cap of $237.09 million, a PE ratio of -6.56 and a beta of 1.38. MaxCyte, Inc. has a one year low of $2.21 and a one year high of $5.26. The firm's 50 day moving average price is $2.81 and its two-hundred day moving average price is $3.61.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $10.39 million during the quarter, compared to analyst estimates of $9.05 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. On average, research analysts expect that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on MXCT shares. Stifel Nicolaus dropped their target price on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price objective on MaxCyte and gave the company a "buy" rating in a report on Wednesday, March 12th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.